GE, Abbott call off $8.1B diagnostics deal

GE wasn't able to complete its purchase of two diagnostics units from Abbott Laboratories. Last January GE had announced that it would pay $8.1 billion for Abbott's laboratory-testing unit and blood-analysis division. For GE, the move would have greatly expanded its fast-growing healthcare division with a big effort involving in vitro diagnostics, while Abbott was looking to concentrate on more lucrative efforts of its own. GE said that it couldn't agree to a final set of terms and conditions. Analysts say that a recent warning letter regarding an Abbott facility in Irving, Texas may have been at the root of the trouble.

- see Abbott's release
- read the report from the International Herald Tribune

Related Articles:
Abbott deal puts focus squarely on pharma. Report
GE negotiating for Abbott diagnostics unit. Report
JPMorgan, GE make healthcare acquisitions. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.